Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › WA › Pullman › NPI 1366446767
Clinic

Public Hospital District #1-A of Whitman County

Public Hospital District #1-A of Whitman County was paid $20.36M by Medicaid between Jan 2018 and Dec 2024, across 196 billing codes. Its largest line is 99283, emergency room visit (moderate) — 15% of everything it billed.

33Billing provider infoPUBLIC HOSPITAL DISTRICT #1-A OF WHITMAN COUNTY
PULLMAN, WA 99163
33aNPI1366446767assigned 06/13/2005
33bProvider typeUrgent Care Clinic/Center
28Total paid$20.36M
24GClaims249,448
24DCodes billed196
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Urgent Care Clinic/Center providers in Washington

Rank by total paid#2 of 15
Median peer was paid$1.01M
This provider vs. median20×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$200K$400K$600K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201830,195$2.06M
201932,467$2.29M
202026,211$1.92M
202134,725$2.58M
202236,368$2.80M
202343,911$4.14M
2024incomplete45,571$4.59M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 15% 21,118 19,097 $3.02M
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 11% 10,567 9,536 $2.20M
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 10% 3,565 2,840 $2.09M
74177 Computed tomography, abdomen and pelvis; with contrast material 6.7% 1,824 1,718 $1.35M
99282 Emergency department visit for the evaluation and management, low to moderate severity 3.9% 6,876 6,362 $795K
70450 Computed tomography, head or brain; without contrast material 3.4% 1,499 1,409 $687K
80053 Comprehensive metabolic panel 3.1% 12,850 10,935 $629K
96361 Intravenous infusion, hydration; each additional hour 2.9% 3,685 3,102 $596K
92507 Treatment of speech, language, voice, communication, and/or auditory processing disorder 2.7% 5,717 2,240 $546K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion 2.5% 9,096 3,482 $513K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour 2.2% 3,229 2,492 $441K
G0378 Hospital observation service, per hour 2.0% 1,013 510 $415K
184 more codes
97530 Therapeutic activities, direct patient contact, each 15 minutes 1.8% 3,628 $372K
97140 Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) 1.5% 4,988 $309K
99213 Doctor's office visit, returning patient (routine) 1.5% 4,275 $301K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report 1.4% 4,826 $294K
99214 Doctor's office visit, returning patient (more involved) 1.4% 3,659 $292K
71046 Radiologic examination, chest; 2 views 1.3% 2,079 $256K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 1.2% 14,470 $243K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 1.1% 2,168 $218K
71045 Radiologic examination, chest; single view <1% 2,824 $190K
84443 Thyroid stimulating hormone (TSH) <1% 4,127 $172K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 1,123 $166K
99281 Emergency department visit for the evaluation and management, self-limited or minor <1% 2,745 $158K
84484 <1% 3,171 $149K
74176 Computed tomography, abdomen and pelvis; without contrast material <1% 225 $149K
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete <1% 410 $148K
96375 Therapeutic injection; each additional sequential IV push <1% 3,627 $134K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 342 $133K
80048 Basic metabolic panel (calcium, ionized) <1% 2,960 $130K
36415 Collection of venous blood by venipuncture <1% 14,356 $129K
97112 Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination <1% 1,707 $106K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 326 $101K
87086 Culture, bacterial; quantitative colony count, urine <1% 3,044 $96K
80061 Lipid panel <1% 2,003 $91K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance <1% 3,700 $90K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 4,472 $87K
73630 <1% 536 $76K
81001 <1% 3,637 $75K
73610 <1% 493 $74K
83690 <1% 3,011 $72K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 1,579 $68K
97161 <1% 1,104 $67K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 1,747 $66K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 763 $64K
71275 Computed tomographic angiography, chest, with contrast material <1% 78 $62K
83036 Hemoglobin; glycosylated (A1C) <1% 2,165 $62K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel <1% 2,094 $60K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 2,816 $58K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 793 $56K
83880 <1% 776 $55K
84703 <1% 1,804 $52K
81025 <1% 1,974 $51K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 737 $50K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 695 $48K
85379 <1% 1,001 $45K
86140 <1% 1,390 $45K
87081 <1% 1,570 $43K
87426 Infectious agent antigen detection, SARS-CoV-2 (COVID-19) <1% 438 $43K
76830 Ultrasound, transvaginal <1% 167 $41K
83735 <1% 1,930 $39K
G0463 Hospital outpatient clinic visit for assessment and management of a patient <1% 233 $38K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 963 $38K
81003 <1% 2,504 $37K
86780 <1% 685 $37K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 363 $36K
97803 <1% 418 $35K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 1,929 $35K
J3010 Injection, fentanyl citrate, 0.1 mg <1% 1,813 $34K
87077 <1% 1,452 $31K
J7030 Infusion, normal saline solution , 1000 cc <1% 1,615 $28K
72100 <1% 199 $28K
87400 <1% 395 $28K
73562 <1% 190 $28K
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 1,612 $27K
87186 <1% 596 $25K
96376 <1% 761 $25K
82962 <1% 2,149 $23K
J0131 Injection, acetaminophen, not otherwise specified,10 mg <1% 393 $22K
86803 <1% 269 $22K
85027 <1% 1,524 $21K
99392 Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) <1% 216 $21K
85610 <1% 1,710 $18K
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 1,018 $18K
87340 <1% 445 $17K
J2704 Injection, propofol, 10 mg <1% 798 $16K
76801 <1% 58 $16K
J7120 Ringers lactate infusion, up to 1000 cc <1% 834 $16K
80050 General health panel <1% 115 $15K
86885 <1% 571 $15K
73030 <1% 100 $14K
J0134 Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg <1% 247 $14K
84439 <1% 471 $13K
J3490 Unclassified drugs <1% 481 $13K
J7050 Infusion, normal saline solution, 250 cc <1% 969 $13K
70551 Magnetic resonance imaging, brain; without contrast material <1% 12 $13K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies <1% 149 $12K
74018 <1% 94 $12K
82728 <1% 282 $12K
87430 <1% 274 $11K
85652 <1% 588 $11K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 353 $11K
97802 <1% 84 $11K
J1170 Injection, hydromorphone, up to 4 mg <1% 504 $10K
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour <1% 75 $10K
99391 Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) <1% 95 $9K
96413 Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance <1% 36 $9K
72148 Magnetic resonance imaging, lumbar spine; without contrast material <1% 12 $8K
73130 <1% 65 $8K
99393 Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) <1% 83 $8K
84145 <1% 102 $8K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 567 $8K
94762 <1% 99 $8K
99215 Doctor's office visit, returning patient (complex) <1% 100 $7K
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) <1% 1,861 $7K
84702 <1% 136 $7K
97113 <1% 67 $7K
77067 Screening mammography, bilateral, including computer-aided detection <1% 39 $7K
83605 <1% 247 $6K
87070 <1% 241 $6K
59025 Fetal non-stress test <1% 32 $6K
73110 <1% 45 $6K
97535 Self-care/home management training, each 15 minutes <1% 81 $6K
86850 <1% 115 $5K
96127 <1% 649 $5K
82550 <1% 231 $5K
80143 <1% 56 $5K
86900 <1% 269 $5K
80179 <1% 55 $5K
76815 Ultrasound, pregnant uterus, real time with image documentation, limited <1% 20 $5K
A9577 Injection, gadobenate dimeglumine (multihance), per ml <1% 101 $5K
83540 <1% 147 $4K
81002 <1% 296 $4K
80076 <1% 84 $4K
76811 Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed <1% 13 $4K
85651 <1% 190 $3K
86901 <1% 268 $3K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 242 $3K
J3475 Injection, magnesium sulfate, per 500 mg <1% 143 $3K
82570 <1% 176 $3K
85007 <1% 455 $3K
90460 Immunization administration through 18 years of age via any route, first or only component <1% 289 $2K
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 153 $2K
97162 <1% 38 $2K
86762 <1% 52 $2K
82670 <1% 29 $2K
J0690 Injection, cefazolin sodium, 500 mg <1% 90 $2K
81015 <1% 266 $2K
91320 <1% 18 $2K
90686 <1% 156 $2K
82607 <1% 52 $2K
94664 <1% 40 $2K
J2060 Injection, lorazepam, 2 mg <1% 110 $2K
80320 <1% 207 $2K
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 89 $2K
A9585 Injection, gadobutrol, 0.1 ml <1% 67 $2K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward <1% 46 $2K
77063 Screening digital breast tomosynthesis, bilateral <1% 39 $2K
36416 <1% 225 $2K
84402 <1% 24 $1K
87040 <1% 37 $1K
84403 <1% 57 $1K
83655 <1% 83 $1K
90715 <1% 73 $1K
82150 <1% 38 $1K
84100 <1% 54 $1K
90656 <1% 220 $1K
87205 <1% 39 $1K
J0136 Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg <1% 16 $981.43
83550 <1% 77 $931.19
97165 <1% 18 $891.29
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 29 $811.78
J2270 Injection, morphine sulfate, up to 10 mg <1% 35 $754.87
82950 <1% 26 $682.26
90480 <1% 39 $673.10
99203 Doctor's office visit, new patient (routine) <1% 12 $550.44
80047 <1% 15 $508.34
J0665 Injection, bupivicaine, not otherwise specified, 0.5 mg <1% 24 $446.46
87806 <1% 221 $378.78
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg <1% 15 $282.63
85014 <1% 40 $275.08
85018 <1% 58 $250.73
0202U Oncology (prostate), multianalyte, gene expression profiling <1% 90 $234.23
J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg <1% 60 $220.56
85730 <1% 15 $167.63
93010 Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only <1% 326 $158.76
90671 <1% 12 $137.83
96110 Developmental screening, with scoring and documentation, per standardized instrument <1% 13 $137.60
90461 <1% 15 $124.82
87147 <1% 12 $108.30
99177 <1% 40 $96.81
80329 <1% 34 $91.46
11721 <1% 12 $78.33
80332 <1% 32 $63.78
G0659 Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes 0% 55 $0.00
A9270 Non-covered item or service 0% 1,995 $-1769.38

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialFORGE, MATT (CHIEF EXECUTIVE OFFICER)